Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.

Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.
复制标题

DOI:
10.1002/ijc.27512
复制
发表时间:
2012-11-15
影响因子:
6.4
通讯作者:
Madhusudan, Srinivasan
Madhusudan, Srinivasan
中科院分区:
医学1区
文献类型:
--
作者:
Sultana, Rebeka;McNeill, Daniel R.;Abbotts, Rachel;Mohammed, Mohammed Z.;Zdzienicka, Malgorzata Z.;Qutob, Haitham;Seedhouse, Claire;Laughton, Charles A.;Fischer, Peter M.;Patel, Poulam M.;Wilson, David M., III;Madhusudan, Srinivasan

文献摘要

参考文献

被引文献

相似文献

无嘌呤/无嘧啶(AP)位点是DNA碱基切除修复(BER)过程中由人类AP内切酶1 (APE1)处理的一种必需的细胞毒性中间体。APE1对BER至关重要,也是癌症治疗中一个新兴的药物靶点。我们已经分离出新的APE1小分子抑制剂。在目前的研究中,我们研究了APE1抑制剂在DNA双链断裂(DSB)修复缺陷和熟练细胞中诱导合成致死的能力;a)中国仓鼠(CH)细胞:BRCA2缺陷(V-C8), ATM缺陷(V-E5),野生型(V79)和BRCA2逆转(V-C8(Rev1))。b)人类癌细胞:BRCA1缺陷(MDA-MB-436), BRCA1精通(MCF-7), BRCA2缺乏(CAPAN-1和HeLa SilenciX细胞),BRCA2精通(PANC1和对照SilenciX细胞)。我们还使用ATM抑制剂和DNA-PKcs抑制剂(DSB抑制剂)测试了表达APE1显性阴性形式的CH卵巢细胞(E8细胞)的合成致死率(SL)。APE1抑制剂在BRCA和ATM缺陷细胞中具有合成致死性。APE1抑制导致DNA dsb积累和G2/M细胞周期阻滞。在ATM或DNA-PKcs抑制剂处理的表达APE1的显性阴性形式的CH细胞中也证明了合成致死性。我们认为,APE1是一种很有前景的抗癌合成致死性靶点。
An apurinic/apyrimidinic (AP) site is an obligatory cytotoxic intermediate in DNA Base Excision Repair (BER) that is processed by human AP endonuclease 1 (APE1). APE1 is essential for BER and an emerging drug target in cancer. We have isolated novel small molecule inhibitors of APE1. In the current study we have investigated the ability of APE1 inhibitors to induce synthetic lethality in a panel of DNA double strand break (DSB) repair deficient and proficient cells; a) Chinese hamster (CH) cells: BRCA2 deficient (V-C8), ATM deficient (V-E5), wild type (V79) and BRCA2 revertant (V-C8(Rev1)). b) Human cancer cells: BRCA1 deficient (MDA-MB-436), BRCA1 proficient (MCF-7), BRCA2 deficient (CAPAN-1 and HeLa SilenciX cells), BRCA2 proficient (PANC1 and control SilenciX cells). We also tested synthetic lethality (SL) in CH ovary cells expressing a dominant–negative form of APE1 (E8 cells) using ATM inhibitors and DNA-PKcs inhibitors (DSB inhibitors). APE1 inhibitors are synthetically lethal in BRCA and ATM deficient cells. APE1 inhibition resulted in accumulation of DNA DSBs and G2/M cell cycle arrest. Synthetic lethality was also demonstrated in CH cells expressing a dominant–negative form of APE1 treated with ATM or DNA-PKcs inhibitors. We conclude that APE1 is a promising synthetic lethality target in cancer.
分离DNA碱基切除修复的小分子抑制剂。
DOI: 10.1093/nar/gki781
发表时间: 2005
影响因子: 14.9
作者:
Madhusudan, S;Smart, F;Shrimpton, P;Parsons, JL;Gardiner, L;Houlbrook, S;Talbot, DC;Hammonds, T;Freemont, PA;Sternberg, MJE;Dianov, GL;Hickson, ID
通讯作者: Hickson, ID
DOI: 10.1073/pnas.88.24.11450
发表时间: 1991-12-01
影响因子: 11.1
作者:
DEMPLE, B;HERMAN, T;CHEN, DS
通讯作者: CHEN, DS
DOI: 10.1016/j.jmb.2008.03.053
发表时间: 2008-05-23
影响因子: 5.6
作者:
Berquist, Brian R.;McNeill, Daniel R.;Wilson, David M., III
通讯作者: Wilson, David M., III
DOI: 10.1196/annals.1339.049
发表时间: 2005-01-01
期刊: TUMOR PROGRESSION AND THERAPEUTIC RESISTANCE
影响因子: --
作者:
Bindra, RS;Schaffer, PJ;Glazer, PM
通讯作者: Glazer, PM
DOI: 10.1158/1078-0432.ccr-10-0526
发表时间: 2010-09-15
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
Annunziata CM;O'Shaughnessy J
通讯作者: O'Shaughnessy J